Transparency Market Research Liver Diseases Therapeutics Market Global Industry Analysis, Size, Share, Trends And Forecast 2012 – 2018
Single User License:
USD 4595 Multi User License:
USD 7595 Corporate User License:
USD 10595
Published Date 16-Jan-2013
112 Page Report
Buy Now
Request Sample
Press Release
Liver Diseases Therapeutics Market is Expected to Reach USD 10.9 Billion Globally in 2018: Transparency Market Research
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Liver Diseases Therapeutics Market
REPORT DESCRIPTION According to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018", the global liver diseases therapeutics market was worth USD 6.5 billion in 2011 and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6% from 2012 to 2018. In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018. Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However sideeffects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market. Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=799 Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future. Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.
2 Transparency Market Research
Liver Diseases Therapeutics Market
TABLE OF CONTENT
CHAPTER 1 PREFACE 1.1 REPORT DESCRIPTION 1.2 RESEARCH METHODOLOGY
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 MARKET OVERVIEW 3.1 INTRODUCTION 3.2 MARKET SIZE 3.3 COMPARATIVE ANALYSIS OF GLOBAL LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS, 2011 & 2018 3.4 LIVER DISEASES THERAPEUTICS MARKET DYNAMICS 3.4.1 DRIVERS 3.4.1.1 Aging population inducing chronic liver diseases such as hepatitis and liver cancer 3.4.1.2 Increasing global prevalence of liver diseases 3.4.1.3 High unmet needs exist in the liver cancer therapeutics 3.4.1.4 Increased vaccination in emerging economies 3.4.2 LIVER DISEASE THERAPEUTICS MARKET DRIVERS IMPACT ANALYSIS 3.4.3 RESTRAINTS 3.4.3.1 Side-effects and risks 3.4.3.2 FDA approvals and other government regulations
3 Transparency Market Research
Liver Diseases Therapeutics Market
3.4.3.3 Availability of alternate treatment procedures 3.4.4 LIVER DISEASE THERAPEUTICS MARKET RESTRAINTS IMPACT ANALYSIS 3.4.5 OPPORTUNITIES 3.4.5.1 Strong pipeline drugs 3.4.5.2 Emerging economies in Asia, Latin America and Eastern European countries 3.4.5.3 Consolidation opportunities in the healthcare industry 3.5 PORTER’S FIVE FORCES ANALYSIS FOR LIVER DISEASES THERAPEUTICS MARKET 3.5.1 BARGAINING POWER OF SUPPLIERS 3.5.2 BARGAINING POWER OF BUYERS 3.5.3 THREAT OF NEW ENTRANTS 3.5.4 THREAT OF SUBSTITUTES 3.5.5 COMPETITIVE RIVALRY
Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
CHAPTER 4 LIVER DISEASES CLASSIFICATION AND THERAPY OPTIONS 4.1 ALCOHOL INDUCED LIVER DISEASE 4.1.1 OVERVIEW 4.1.2 EPIDEMIOLOGY 4.1.3 ETIOLOGY 4.1.4 SYMPTOMS 4.1.5 PATHOPHYSIOLOGY 4.1.6 TREATMENT PATTERN AND THERAPY OPTIONS
4 Transparency Market Research
Liver Diseases Therapeutics Market
4.1.6.1 Anabolic Steroids 4.1.6.2 Alcohol Abuse Drugs 4.2 AUTOIMMUNE LIVER DISORDER 4.2.1 AUTOIMMUNE HEPATITIS (AIH) 4.2.1.1 OVERVIEW 4.2.1.2 EPIDEMIOLOGY 4.2.1.3 ETIOLOGY 4.2.1.4 SYMPTOMS 4.2.1.5 PATHOPHYSIOLOGY 4.2.1.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.2.1.6.1 Antimetabolites 4.2.1.6.2 Corticosteroids 4.3 HEPATOCELLULAR CARCINOMA 4.3.1 OVERVIEW 4.3.2 EPIDEMIOLOGY 4.3.3 ETIOLOGY 4.3.4 SYMPTOMS 4.3.5 PATHOPHYSIOLOGY 4.3.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.3.6.1 Chemotherapy 4.3.6.2 Targeted Therapy 4.4 NON-ALCOHOLIC FATTY LIVER DISEASE 4.4.1 OVERVIEW 4.4.2 EPIDEMIOLOGY
5 Transparency Market Research
Liver Diseases Therapeutics Market
4.4.3 ETIOLOGY 4.4.4 SYMPTOMS 4.4.5 PATHOPHYSIOLOGY 4.4.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.4.6.1 Gallstone solubilising drugs 4.5 VIRAL/HEPATITIS LIVER DISORDER 4.5.1 HEPATITIS A 4.5.1.1 OVERVIEW 4.5.1.2 EPIDEMIOLOGY 4.5.1.3 ETIOLOGY 4.5.1.4 SYMPTOMS 4.5.1.5 PATHOPHYSIOLOGY 4.5.1.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.1.6.1 Vaccines 4.5.1.6.2 Immunoglobulins 4.5.2 HEPATITIS B 4.5.2.1 OVERVIEW 4.5.2.2 EPIDEMIOLOGY 4.5.2.3 ETIOLOGY 4.5.2.4 SYMPTOMS 4.5.2.5 PATHOPHYSIOLOGY 4.5.2.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.2.6.1 Antiviral drugs 4.5.2.6.2 Immunoglobulins
6 Transparency Market Research
Liver Diseases Therapeutics Market
4.5.2.6.3 Vaccines
Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
4.5.3 HEPATITIS C 4.5.3.1 OVERVIEW 4.5.3.2 EPIDEMIOLOGY 4.5.3.3 ETIOLOGY 4.5.3.4 SYMPTOMS 4.5.3.5 PATHOPHYSIOLOGY 4.5.3.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.3.6.1 Antiviral drugs 4.5.4 HEPATITIS D 4.5.4.1 OVERVIEW 4.5.4.2 EPIDEMIOLOGY 4.5.4.3 ETIOLOGY 4.5.4.4 SYMPTOMS 4.5.4.5 PATHOPHYSIOLOGY 4.5.4.6 TREATMENT PATTERN AND THERAPY OPTIONS 4.5.5 HEPATITIS E 4.5.5.1 OVERVIEW 4.5.5.2 EPIDEMIOLOGY 4.5.5.3 ETIOLOGY
7 Transparency Market Research
Liver Diseases Therapeutics Market
4.5.5.4 SYMPTOMS 4.5.5.5 PATHOPHYSIOLOGY 4.5.5.6 TREATMENT PATTERN AND THERAPY OPTIONS
CHAPTER 5 LIVER DISEASES THERAPEUTICS MARKET, BY DRUG CLASS 5.1 IMMUNOSUPPRESSANTS 5.1.1 GLOBAL IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.2 CHEMOTHERAPY DRUGS 5.2.1 GLOBAL CHEMOTHERAPY DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.3 TARGETED THERAPY DRUGS 5.3.1 GLOBAL TARGETED THERAPY MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.4 VACCINES 5.4.1 GLOBAL VACCINES MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.5 ANTI-VIRAL DRUGS 5.5.1 GLOBAL ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.6 IMMUNOGLOBULINS 5.6.1 GLOBAL IMMUNOGLOBULINS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION) 5.7 CORTICOSTERIODS 5.7.1 GLOBAL CORTICOSTERIODS MARKET FOR LIVER DISEASE THERAPEUTICS, 2010 – 2018 (USD MILLION)
CHAPTER 6 COMPETITIVE LANDSCAPE
8 Transparency Market Research
Liver Diseases Therapeutics Market
6.1 MARKET SHARE OF KEY PLAYERS IN LIVER DISEASES THERAPEUTICS MARKET BY DRUG CLASS 6.1.1 MARKET SHARE OF KEY PLAYERS FOR IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASES 6.1.2 MARKET SHARE OF KEY PLAYERS FOR VACCINES MARKET FOR LIVER DISEASES 6.1.3 MARKET SHARE OF KEY PLAYERS FOR ANTI-VIRAL DRUGS MARKET FOR LIVER DISEASES 6.1.4 MARKET SHARE OF KEY PLAYERS FOR TARGETED THERAPY FOR LIVER DISEASES 6.1.5 NEW ENTRANTS (PHASE III) 6.1.6 COMPETITIVE STRATEGY BY KEY PLAYERS 6.1.6.1 Investments in R&D and clinical studies 6.1.6.2 Entering the emerging economies 6.1.6.3 Investing in different segments of the market 6.1.7 COMPETITIVE STRATEGY BY NEW ENTRANTS 6.1.8 AGREEMENTS AND COLLABORATIONS
CHAPTER 7 RECOMMENDATIONS 7.1 MARKET STRATEGY FOR SUCCESS 7.2 BARRIERS TO BE CONSIDERED
Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
CHAPTER 8 COMPANY PROFILES 8.1 ABBOTT LABORATORIES 8.1.1 COMPANY OVERVIEW 8.1.2 FINANCIAL OVERVIEW
9 Transparency Market Research
Liver Diseases Therapeutics Market
8.1.3 BUSINESS STRATEGIES 8.1.3.1 Significant R&D investments for new products development 8.1.3.2 Investing in emerging markets 8.1.3.3 Conducting clinical trials 8.1.4 PRODUCT PORTFOLIO 8.1.5 RECENT DEVELOPMENTS 8.2 ASTELLAS PHARMA INC. 8.2.1 COMPANY OVERVIEW 8.2.2 FINANCIAL OVERVIEW 8.2.3 BUSINESS STRATEGIES 8.2.3.1 Investing in emerging economies 8.2.3.2 Investing in research and development 8.2.4 PRODUCT PORTFOLIO 8.2.5 RECENT DEVELOPMENTS 8.3 BRISTOL-MYERS SQUIBB 8.3.1 COMPANY OVERVIEW 8.3.2 FINANCIAL OVERVIEW 8.3.3 BUSINESS STRATEGIES 8.3.3.1 Mergers, acquisitiosn and strategic development 8.3.3.2 Investing in research and development 8.3.4 PRODUCT PORTFOLIO 8.3.5 RECENT DEVELOPMENTS 8.4 GILEAD SCIENCES 8.4.1 COMPANY OVERVIEW
10 Transparency Market Research
Liver Diseases Therapeutics Market
8.4.2 FINANCIAL OVERVIEW 8.4.3 BUSINESS STRATEGIES 8.4.3.1 Innovative new products 8.4.3.2 Investing in research and development 8.4.4 PRODUCT PORTFOLIO 8.4.5 RECENT DEVELOPMENTS 8.5 GLAXOSMITHKLINE PLC 8.5.1 COMPANY OVERVIEW 8.5.2 FINANCIAL OVERVIEW 8.5.3 BUSINESS STRATEGIES 8.5.3.1 Research and development investments 8.5.3.2 Delivering new products 8.5.4 PRODUCT PORTFOLIO 8.5.5 RECENT DEVELOPMENTS 8.6 F. HOFFMANN-LA ROCHE LTD 8.6.1 COMPANY OVERVIEW 8.6.2 FINANCIAL OVERVIEW 8.6.3 BUSINESS STRATEGIES 8.6.3.1 Strategic alliance initiative 8.6.3.2 Investing in research and development 8.6.4 PRODUCT PORTFOLIO 8.6.5 RECENT DEVELOPMENTS 8.7 MERCK & CO. INC 8.7.1 COMPANY OVERVIEW
11 Transparency Market Research
Liver Diseases Therapeutics Market
8.7.2 FINANCIAL OVERVIEW 8.7.3 BUSINESS STRATEGIES 8.7.3.1 R&D initiatives 8.7.3.2 Strategic alliance 8.7.3.3 Corporate social responsibility and awareness 8.7.4 PRODUCT PORTFOLIO 8.7.5 RECENT DEVELOPMENTS 8.8 NOVARTIS AG 8.8.1 COMPANY OVERVIEW 8.8.2 FINANCIAL OVERVIEW 8.8.3 BUSINESS STRATEGIES 8.8.3.1 Strategic alliance 8.8.3.2 Investing in research and development 8.8.4 PRODUCT PORTFOLIO 8.8.5 RECENT DEVELOPMENTS 8.9 SANOFI S.A 8.9.1 COMPANY OVERVIEW 8.9.2 FINANCIAL OVERVIEW 8.9.3 BUSINESS STRATEGIES 8.9.3.1 Business Diversification 8.9.3.2 Research and development initiative 8.9.4 PRODUCT PORTFOLIO 8.9.5 RECENT DEVELOPMENTS 8.10 PFIZER INC.
12 Transparency Market Research
Liver Diseases Therapeutics Market
8.10.1 COMPANY OVERVIEW 8.10.2 FINANCIAL OVERVIEW 8.10.3 BUSINESS STRATEGIES 8.10.3.1 Investing in research and development 8.10.4 PRODUCT PORTFOLIO 8.10.5 RECENT DEVELOPMENTS 8.11 TAKEDA PHARMACEUTICAL 8.11.1 COMPANY OVERVIEW 8.11.2 FINANCIAL OVERVIEW 8.11.3 BUSINESS STRATEGIES 8.11.3.1 Investing in emerging economies 8.11.3.2 Investing in research and development 8.11.4 PRODUCT PORTFOLIO 8.11.5 RECENT DEVELOPMENTS
Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html
8.12 VALEANT PHARMACEUTICALS 8.12.1 COMPANY OVERVIEW 8.12.2 FINANCIAL OVERVIEW 8.12.3 BUSINESS STRATEGIES 8.12.3.1 Strategic alliance 8.12.4 PRODUCT PORTFOLIO
13 Transparency Market Research
Liver Diseases Therapeutics Market
8.12.5 RECENT DEVELOPMENTS 8.13 WATSON PHARMACEUTICALS, INC. 8.13.1 COMPANY OVERVIEW 8.13.2 FINANCIAL OVERVIEW 8.13.3 BUSINESS STRATEGIES 8.13.3.1 Investing in generic and biosimilar segments 8.13.3.2 Investing in research and development 8.13.4 PRODUCT PORTFOLIO 8.13.5 RECENT DEVELOPMENTS
About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/
Blog: http://tmrresearch.wordpress.com/
14 Transparency Market Research